Top

generating

the breakthroughs to heal

Press releases

We’re meeting milestones in our quest to accelerate healing.

2025

2024

20 November 2024

Noveome Biotherapeutics, Inc. Announces Issuance of U.S. Patent No. 12,121,546 Entitled, “Treatment of Systemic Inflammatory Responses”

14 November 2024

Noveome Biotherapeutics, Inc. Announces Completion of Treatment of the First Baby in its Phase 1-2 Clinical Trial Evaluating ST266 in the Treatment of Necrotizing Enterocolitis in Premature Infants

2023

12 December 2023

Noveome Biotherapeutics, Inc. Receives FDA Notification to Proceed with its Phase 1-2 Clinical Trial in Treatment of NEC

17 August 2023

Noveome Biotherapeutics, Inc. Completes First Close of $40 Million Series E Financing to Support Clinical Trials in NEC

2022

16 November 2022

Noveome Biotherapeutics, Inc. Announces New Appointments to Board of Directors

24 May 2022

Noveome Biotherapeutics, Inc. Receives Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Necrotizing Enterocolitis in Neonates

2021

23 June 2021

Noveome Biotherapeutics, Inc. Commences Phase 1 Clinical Study of ST266 Application for Infectious Disease (including COVID-19)

7 June 2021

Noveome Biotherapeutics, Inc. Announces Preliminary Results of its Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 In Glaucoma Suspect Patients

1 June 2021

Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement For SipNose Cribriform Targeted Device

24 May 2021

Noveome Biotherapeutics, Inc. Announces Christopher J. P. Velis as Chief Executive Officer

8 March 2021

Noveome Biotherapeutics, Inc. Makes New Appointment to Board of Directors

22 February 2021

Noveome Biotherapeutics, Inc. To Present At The 9th Annual Virtual Neurodegenerative Drug Development Summit

1 February 2021

Noveome Biotherapeutics, Inc. and Walter Reed Army Institute of Research to Study Noveome’s Lead Product Candidate ST266 in Traumatic Brain Injury

27 January 2021

Noveome Biotherapeutics, Inc. to Present at 10th Annual Glaucoma 360 Virtual Meeting

25 January 2021

Noveome Biotherapeutics, Inc. Makes New Appointment to Board of Directors

6 January 2021

Noveome Biotherapeutics, Inc. Publishes Preclinical Results Demonstrating Neuroprotective Properties of ST266 Requires Full Complement of Proteins

2020

3 November 2020

Noveome Biotherapeutics, Inc. to Present at the 10th Annual Traumatic Brain Injury Conference (Virtual), November 2-4, 2020

22 October 2020

Noveome Biotherapeutics, Inc. Announces New Appointments to its Board of Directors

21 October 2020

Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results Demonstrating the Neuroprotective Properties of Amnion-derived Multipotent Progenitor Cells in Spinal Cord and Retinal Ganglion Cells

31 August 2020

Noveome Biotherapeutics, Inc. Co-Leads Pre-Conference Workshop at Digital 2020 Blood-Brain Barrier Summit

12 June 2020

Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects

12 May 2020

Singota Solutions Collaborates with Noveome Biotherapeutics, Inc. to Manufacture Promising Therapy to Treat Severe Condition in People Infected with COVID-19

7 May 2020

Noveome Biotherapeutics Receives $4 Million Grant from Commonwealth of Pennsylvania

30 March 2020

Noveome Biotherapeutics, Inc. Launches Program to Evaluate ST266 for the Treatment of the Severe Inflammatory Response Associated with COVID-19

24 February 2020

Noveome Biotherapeutics, Inc. To Present At The 8th Annual Neurodegenerative Drug Development Summit

5 February 2020

Noveome Biotherapeutics, Inc. to Present at 9th Annual Glaucoma 360 Meeting

2019

24 October 2019

Noveome Biotherapeutics, Inc. Announces Appointment of Kevin E. McCracken as Senior Vice President of Operations

3 October 2019

Noveome Biotherapeutics, Inc. To Present At The 2019 Flagship Ophthalmology Innovation Summit

26 September 2019

Noveome Biotherapeutics, Inc. Initiates Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 Targeting the Optic Nerve and Brain

5 September 2019

Noveome Biotherapeutics, Inc. Announces Passing of Board Member, John H. McArthur

13 June 2019

Noveome Biotherapeutics, Inc. Doses First Patient in Phase 2 Open Label Clinical Trial Evaluating Topical Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defects

9 May 2019

Noveome Biotherapeutics, Inc. Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cells

9 April 2019

Noveome Biotherapeutics, Inc. Completes $15 Million Series D Financing to Advance Growing Pipeline of Next-Generation Biologics

2 April 2019

Noveome Biotherapeutics, Inc. to Present at the 18th Annual Needham Healthcare Conference

2018

24 May 2018

Study Advances Novel Treatment for Damaged Optic Nerve

27 April 2018

Patrick Welch Elected to Noveome Board of Directors

3 April 2018

State Grant to Fund Clinical Trials Through Pittsburgh-Israeli Collaboration